Phase I Study of Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors.
Phase of Trial: Phase I
Latest Information Update: 02 Jan 2018
At a glance
- Drugs Monoclonal antibody 3F8 (Primary)
- Indications Neuroblastoma; Solid tumours
- Focus Adverse reactions
- 05 Sep 2017 Planned End Date changed from 1 Aug 2017 to 1 Aug 2018.
- 05 Sep 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 15 Feb 2016 Planned number of patients changed from 72 to 74 as reported by ClinicalTrials.gov record.